Drugs / BW-00112
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06497127 | Feb 2024 → Jun 2026 overdue | hyperlipidemia, combined, 2 | Shanghai Argo Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BW-00112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06497127 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered BW-00112” NCT06497127 ↗ |